ARCT - Arcturus Therapeutics Holdings Inc.

QQQ $ 454.82 $ 1.73 (0.38 %)

DIA $ 398.57 $ -2.04 (-0.52 %)

SPY $ 530.36 $ 0.37 (0.07 %)

TLT $ 91.26 $ -1.31 (-1.43 %)

GLD $ 225.37 $ 2.27 (1.05 %)

Previous Close

$ 38.41

Open

$ 34.90

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 34.90 - $ 38.62

52 Week Range

$ 17.52 - $ 43.81

Volume

1,071,915

Average Volume

Market Cap

1.03B

Beta (5Y Monthly)

$ 1.49

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-14-2024	12-31-2023	10-K
3	11-14-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	03-29-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-09-2022	06-30-2022	10-Q
9	05-09-2022	03-31-2022	10-Q
10	03-01-2022	12-31-2021	10-K
11	11-09-2021	09-30-2021	10-Q
12	08-10-2021	06-30-2021	10-Q
13	05-10-2021	03-31-2021	10-Q
14	03-01-2021	12-31-2020	10-K
15	11-09-2020	09-30-2020	10-Q
16	08-10-2020	06-30-2020	10-Q
17	05-08-2020	03-31-2020	10-Q
18	03-16-2020	12-31-2019	10-K
19	11-08-2019	09-30-2019	10-Q
20	08-14-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

arcturus-therapeutics-early-cystic-fibrosis-trial-results-encouraging---analyst-cautiously-optimistic

Arcturus Therapeutics' Early Cystic Fibros...
05/28/2024 18:55:43

Arcturus Therapeutics' early Phase 1 results show ARCT-032 is safe and well-tolerated, with promising improvements in lung ...

why-applied-dna-sciences-shares-are-trading-lower-by-around-68-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Why Applied DNA Sciences Shares Are Tradin...
05/28/2024 17:24:16

Nvidia, Insmed, Agios Pharmaceuticals And ...
05/28/2024 14:31:28

Market-Moving News for May 28th
05/28/2024 12:41:15

CORT: 41% | Corcept Therapeutics shares are trading higher after the company announced that its Phase 3 GRACE trial met its pri...

Arcturus Therapeutics Reports Phase 1b Dat...
05/28/2024 10:33:14

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program Business Wire Arcturus to present new Phase ...

Achilles Therapeutics And Arcturus Therape...
05/22/2024 11:07:04

CSL and Arcturus Therapeutics Announce Nat...
05/20/2024 12:42:20

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results...

Canaccord Genuity Maintains Buy on Arcturu...
05/10/2024 18:30:57

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and lowers the price target ...

elon-musk-breaks-ranks-with-gop-by-praising-genetic-engineering-tech-that-helped-fight-covid-19-digital-medicine-with-incredible-potential

Elon Musk Breaks Ranks With GOP By Praisin...
05/09/2024 09:01:47

Elon Musk has come off as a flagbearer of the mRNA technology, which is seen holding out a lot of promise by scientists.

Arcturus Therapeutics Q1 EPS $(1.00) Beats...
05/08/2024 20:03:35

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of...

HC Wainwright & Co. Reiterates Buy on Arct...
03/20/2024 10:44:28

HC Wainwright & Co. reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price target.

The Analyst Verdict: Arcturus Therapeutics...
03/11/2024 12:01:29

Canaccord Genuity Maintains Buy on Arcturu...
03/11/2024 11:51:35

Canaccord Genuity analyst Whitney Ijem maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target ...

HC Wainwright & Co. Reiterates Buy on Arct...
03/08/2024 14:42:42

HC Wainwright & Co. analyst Ed Arce reiterates Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and maintains $60 price ta...

Recap: Arcturus Therapeutics Q4 Earnings
03/07/2024 21:05:07

Arcturus Therapeutics Q4 2023 GAAP EPS $(0...
03/07/2024 21:03:49

Arcturus Therapeutics (NASDAQ:ARCT) reported quarterly losses of $(0.320) per share which beat the analyst consensus estimate o...

Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

Earnings Preview: Arcturus Therapeutics
03/06/2024 15:01:58

Arcturus Therapeutics Receives Orphan Medi...
02/22/2024 13:33:35

Citigroup Maintains Buy on Arcturus Therap...
02/08/2024 16:04:52

Citigroup analyst Yigal Nochomovitz maintains Arcturus Therapeutics (NASDAQ:ARCT) with a Buy and raises the price target fro...